# Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)

> **NCT04174716** · PHASE1,PHASE2 · COMPLETED · sponsor: **Idience Co., Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Solid Tumors
- Homologous Recombination Repair Gene Mutation
- Homologous Recombination Deficiency

## Interventions

- **DRUG:** IDX-1197

## Key facts

- **NCT ID:** NCT04174716
- **Lead sponsor:** Idience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-06
- **Primary completion:** 2023-03-31
- **Final completion:** 2024-06-28
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04174716

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04174716, "Basket Trial of IDX-1197, a PARP Inhibitor, in Patients With HRR Mutated Solid Tumors (VASTUS)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04174716. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*